Gene/drug composite lipid preparation and preparation method and application thereof

A technology for compounding lipids and preparations, which can be used in drug combinations, gene therapy, pharmaceutical formulations, etc., and can solve problems such as unsatisfactory results.

Active Publication Date: 2021-05-28
SHANGHAI JIAO TONG UNIV
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, no satisfactory results have been found so far whether targeting TGF-β secre

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene/drug composite lipid preparation and preparation method and application thereof
  • Gene/drug composite lipid preparation and preparation method and application thereof
  • Gene/drug composite lipid preparation and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Preparation and Characterization of Example 1 Gene / Drug Composite Lipid Carrier

[0076] (1) Reagent and lipid stock solution: DOTAP / Chol / DPPC stock solution: 25mg / mL, weigh 100mg DOTAP / Chol / DPPC dissolved in 4mL chloroform; DMG-PEG2000 stock solution: 5mg / mL, weigh 20mgDMG - PEG2000 dissolved in 4mL chloroform; ammonium sulfate solution: 200mM, prepared by weighing 1.057g solid ammonium sulfate powder and dissolving it in 40mL ultrapure water;

[0077] (2) Pipette an appropriate amount of DOTAP / Chol / DPPC / DMG-PEG2000 stock solution into a round-bottomed flask with a micro-syringe needle, the molar ratio is 50:40:9:1, add an appropriate amount of chloroform, and place in a 50°C water bath Rotary evaporation to remove organic solvent;

[0078] (3) drying up the organic solvent remaining in the round-bottomed flask of step (2) with nitrogen to make lipid film;

[0079] (4) adding an appropriate amount of 200mM ammonium sulfate solution preheated to 50°C into the lipid fi...

Embodiment 2

[0084] The luciferase gene transfection effect evaluation of embodiment 2 gene / drug composite lipid carrier

[0085] (1) 24 hours in advance, mouse hepatic stellate cells (JS1) were treated with 1*10 4 Seed into a 96-well plate at the density of each well, add 100uL DMEM complete medium containing 10% FBS to each well, and enter the next step after the cell confluency reaches 80%;

[0086] (2) Blank cationic liposomes were co-incubated with pGL3 plasmid at a nitrogen-to-phosphorus ratio of 4:1. Add about 250ng of plasmid to each well, add DMEM medium to a total volume of 100uL per well, and place in a 37°C incubator without serum transfer. Change the medium after 4-6 hours of staining, add complete medium and continue to culture for 24 hours;

[0087] (3) 24 hours after transfection, wash with pre-cooled PBS to remove residual medium, add 50uL cell lysate to each well, lyse at room temperature for 10 minutes, and centrifuge at 4,000rpm in an orifice centrifuge for 2 minutes; ...

Embodiment 3

[0090] Example 3 Efficiency Evaluation of Gene / Drug Composite Lipid Carrier Importing Cy5-siRNA into Hepatic Stellate Cells

[0091] (1) 24 hours in advance of JS1 cells with 1*10 4 Seed into a 96-well plate at the density of each well, add 100uL DMEM complete medium containing 10% FBS to each well, and enter the next step after the cell confluency reaches 80%;

[0092] (2) Blank cationic liposomes were incubated with cy5-siRNA at a nitrogen-to-phosphorus ratio of 4:1 in the dark, and three concentrations of siRNA were set, namely 50nM, 100nM, and 200nM, and DMEM medium was added to make the total volume of each well 100uL. Serum-free transfection in a 37°C incubator;

[0093] (3) Change the medium after 4-6 hours of transfection, wash with pre-warmed PBS three times, and remove unbound free siRNA;

[0094] (4) The transfection efficiency was observed under a fluorescence microscope, and the images were converted into grayscale images using ImageJ software.

[0095] The res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Concentrationaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of biology, in particular to a gene/small molecule compound complex lipid preparation and a preparation method and application thereof, and particularly relates to a gene/drug composite lipid preparation aiming at a TGF-beta/SMAD signal channel and application thereof. Research finds that a positively charged cationic lipid and a negatively charged nucleic acid drug form a lipid complex through electrostatic interaction, and by means of an active drug loading technology of a small molecule compound, a complex lipid carrier capable of simultaneously delivering a gene drug/small molecule compound into the same target cell can be formed.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a gene / small molecular compound compound lipid preparation targeting TGF-β / SMAD signaling pathway and its application. Background technique [0002] The TGF-β / SMAD signaling pathway plays a very important role in many pathological and physiological processes. Dysplasia of intrahepatic connective tissue caused by excessive deposition of diffuse extracellular matrix. [0003] The TGF-β / SMAD signaling pathway plays a very important role in the progression of fibrotic diseases, but due to the pleiotropic effects of TGF-β and its role in other physiological processes such as inflammation regulation and immune suppression, direct inhibition of TGF-β The β signaling pathway may have potential systemic adverse effects. TGF-β1 homozygous deletion mice were accompanied by severe immune and inflammatory system dysfunction, and the mice died in utero or died of multi-organ inflammation within ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K31/517A61K9/127A61P1/16
CPCA61K48/005A61K31/517A61K9/1277A61K47/28A61P1/16A61K2300/00Y02A50/30
Inventor 徐宇虹张新健
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap